Cetraxal Otic
ciprofloxacin otic
Treatment for Otitis ExternaSALVAT Files NDA for its Cetraxal Otic - Ciprofloxacin Otic- 0.2% Solution, for the Treatment of External Otitis
BARCELONA, Spain, June 10, 2005 -- SALVAT today announced that it has submitted a new drug application for their Cetraxal Otic solution, with its convenient, single-dispensing container (SDC) format, with the FDA.
The efficacy and safety of the treatment has been assessed in a 630 patient phase III clinical trial, which is the basis for their application.
"We combined the advantages of a proven, effective antibiotic with a simple, accurate form of administration. The idea behind our product is to reduce unnecessary ingredients thus avoiding unexpected adverse reactions, especially problematic in the pediatric population.
We are convinced that finding the right commercial partner in the US will help us to bring the benefits of this new product to a great number of patients" said Jordi Julve, COO of SALVAT.
About SALVAT
SALVAT is an independent, privately owned, Spanish pharmaceutical
group closely identified with technological innovation and strongly
committed to R&D.
Related Articles:
Salvat Announces the FDA Acceptance of NDA for its Cetraxal Otic Solution - September 14, 2005
Salvat Seeks FDA Approval for its Cetraxal Otic (Ciprofloxacin Otic) 0.2% Solution, for the Treatment of External Otitis - April 18, 2005
New Drug Applications Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
